About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

smiler
Can only buy 70k with Barclays sell at .29

Yet they put the price down not up?

Eirx Therapeutics was 0.03 firmer at 0.27 amid talk of a cancer treatment deal with a US company that could provide a boost to revenues. Gossips talk of a potential sum of 18 mln usd (9.6 mln stg), well above Eirx's 7.0 mln stg market captalisation.

http://www.lse.co.uk/MarketReports.asp?shareprice=&ArticleRef=76005&ArticleHeadline=UK_small_caps_open_sharply_higher_with_blue_chips

I cant understand the sp/ spread ? and yet short of stock?

MM's have probably got a surplus at present Smiler, as soon as that is gone they will want more stock and up the bid price again, until such time as they are running out again, and so it will go on.
kim

could well be kim, interesting to see where this will end up today ?

Tomorrow may be better, if MGI give them a mention later this evening!
kim

laurie, we will probably hear at 2pm ish!!!, although with todays rise I hope we dont get the news till tomorrow...

then we will get good momentum, I have also spoken to a broker and they reckon,,. that these will hit 8p. they reckon this is far bigger than HML ever went to.. I agree

PH Will you be watching the MGI Webcast?

Q306 Financial Results Conference Call
October 18, 2006 - 4:00PM CT
Webcast Events
10/18/06 at 5:00 p.m. ET
Q3 2006 MGI Pharma Earnings Conference Call (Live)
kim

8 mill T trade may see some movement with a bit of luck !

Watch the bid price move up!
kim

well thats it, the MM's have sold the 40mil B trade from last week, they are now short of stock, so now the price will rise pretty quick

It should be noted that Auvation Ltd had out-licensed certain uses of one of its
P450 targets to Zycos Inc. of Lexington, MA, now part of MGI Pharma, Inc.
(NASDAX: MOGN). A cancer vaccine based on the IP licensed from Auvation is
scheduled to enter Phase II clinical trials in Q1 2006. Substantial revenues
can potentially flow from this deal, with milestones paid on entry to each
clinical trial phase, and royalties payable on sales when the drug comes to
market.


The Company has leading expertise in the science of apoptosis (or "programmed
cell death") and is at the forefront of efforts to control this critical
cellular mechanism in order to treat cancer. EiRx has three active programmes
developing drugs that trigger tumour cell death by activating apoptosis. Two of
these are the collaborations with OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and
Sareum mentioned above. Both these initiatives are in the assay development and
screening stages, and are expected to achieve scheduled milestones in early to
mid 2006.

EiRx Therapeutic to get 1st milestone payment as OSI licenses 4 drug targets

LONDON (AFX) - EiRx Therapeutics PLC, the healthcare company specialising in
the control of programmed life and death of cells (apoptosis), said OSI
Pharmaceuticals has opted to license four of its drug targets, thereby
triggering first milestone payment with a potential value of up to 18.8 mln usd.
In a statement, the company said OSI Pharmaceuticals has opted to license
and take forward four of its gene targets into drug discovery for oncology.
A success fee for each target is payable by OSI Pharmaceuticals, as part of
a deal consisting of upfront access and consultancy fees, potential success fees
for each target elected by OSI Pharmaceuticals to license and potential
milestone payments based on successful commercialisation of a novel therapeutic
with respect to each such target.
newsdesk@afxnews.com
http://www.advfn.com/p.php?pid=nmona&cb=1161174802&article=7554608&symbol=LSE%3AERX

Potatohead you have excelled yourself!!!

Not often I trust on other peoples research but I repurchased this morning on a rising price - against all my normal instincts.

Thanks!

I would hold even if news comes laurie, there is more than one bit of news to come in the short term..

OSI, MGI and breast cancer!!!! and then there are the patent approvals, which are now due

Someone just sold at 0.030 and yet mm put the price down to 0.025?

ignore it.. they are short of shares, they dont want anymore buying.. they are scared.. dont blame em, rumour is these are going to 8p

when you think on the breast cancer news we went up to 40, yet today we struggle to get there on the expectation of huge sums of money!!!.. quite rediculous how the mm's play it really, as per John pools interview, the mm's dont understand what the company does and so therefore does not know the value..

and as per j Pool, the SP is significantly undervalued, when he said this the SP was standing at 35.. so we have not even really gone up since he said the sp is undervalued...

says alot really dont it
http://www.wallstreetreporter.com/interview.php?id=18589&player=wma

PH
Can you keep your ramping slightly down or better still on the other side the stuff you have posted above is from 05 May 2004. The OSI website states OSI-930 as finished Phase 1 - not started Phase 2 and OSI-817 as IND-TRACKED (not at phase 1 yet) and states "OSI-817 is a second development candidate to arise from our c-kit/VEGFR program and this molecule could enter clinical development by year end." the sp is rising on speculation of a new deal in addition to any payments that may come from OSI